IP Library Granted Patent US 7,811,794
Granted Patent B2
US 7,811,794 · App. 10/803,180 · Granted Oct 12, 2010

Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof

Assignee: Celera Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,811,794
App. No.
10/803,180
Granted
Oct 12, 2010
Kind
B2
Abstract

The present invention is based on the discovery of genetic polymorphisms that are associated with rheumatoid arthritis. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.

Claims (12)

1. A method of determining that a human has an increased risk for developing positive autoantibody rheumatoid factor (RF+) Rheumatoid Arthritis (RA) comprising:

testing nucleic acid from said human to detect the nucleotide content of a single nucleotide polymorphism (SNP) at position 101 of SEQ ID NO: 5502 or its complement;

wherein a G/G genotype at position 101 of SEQ ID NO:5502, or a C/C genotype at position 101 of the complement of SEQ ID NO:5502, is detected and indicates said human has an increased risk for developing RF+RA.

2. The method of claim 1 in which SEQ ID NO: 5502 is contained within SEQ ID NO: 1688, where SEQ ID NO: 1688 is the genomic sequence of the TRIP (TRAF interacting protein) gene.

3. The method of claim 1 in which the SNP is located at position 6497 of SEQ ID NO: 1688.

4. The method of claim 1 in which said nucleic acid is a nucleic acid extract from a biological sample of said human.

5. The method of claim 4 in which said biological sample is blood, saliva, or buccal cells.

6. The method of claim 1 , wherein said testing step comprises nucleic acid amplification.

7. The method of claim 1 in which the testing is performed by using detection reagents comprising the nucleotide sequences of SEQ ID NO: 6629, SEQ ID NO: 6630, and SEQ ID NO: 6631.

8. The method of claim 1 in which the testing is performed by a process selected from the group consisting of: allele-specific probe hybridization, allele-specific primer extension, allele-specific amplification, sequencing, 5′ nuclease digestion, molecular beacon assay, oligonucleotide ligation assay, size analysis, and single-stranded conformation polymorphism.

9. The method of claim 1 , further comprising correlating the presence of said G/G genotype or said C/C genotype with an increased risk for developing positive autoantibody rheumatoid factor (RF+) Rheumatoid Arthritis (RA).

10. The method of claim 9 , wherein said correlating step is performed by computer software.

Assignments (4)
CHANGE OF NAME Recorded Feb 26, 2010
From: APPLERA CORPORATION
To: APPLIED BIOSYSTEMS INC.
Reel/Frame 023994/0538 →
MERGER Recorded Feb 26, 2010
From: APPLIED BIOSYSTEMS INC.
To: APPLIED BIOSYSTEMS, LLC
Reel/Frame 023994/0587 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2008
From: APPLERA CORPORATION
To: CELERA CORPORATION
Reel/Frame 021561/0124 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2004
From: CARGILL, MICHELE; BEGOVICH, ANN B.; ALEXANDER, HEATHER C.
To: APPLERA CORPORATION
Reel/Frame 015075/0968 →
Continuity (3)
Provisional Application 6045544400 · Mar 18, 2003
Provisional Application 6046524100 · Apr 25, 2003
Related Publication 20070031848A1 · Feb 8, 2007